NCT00437684View on ClinicalTrials.gov

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

PHASE3UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
HIV InfectionsHepatitis C
Interventions
DRUG

LPV/r

200/50 mg 2 cpr bid monotherapy

DRUG

PEG-IFNa 2a

PEG-IFNa 2a 180 mcg/week

DRUG

Ribavirin

Ribavirin 1-1.2 g/day

DRUG

NUCS

Nucleoside Reverse Transcriptase Inhibitors

Trial Locations (1)

20127

RECRUITING

San Raffaele Hospital, Dep. Infectious Diseases, Milan

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

IRCCS San Raffaele

OTHER

NCT00437684 - Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy | Biotech Hunter | Biotech Hunter